MGB Biopharma, the Glasgow-based biopharmaceutical company developing a novel class of anti-infectives, today announces the successful conclusion of its Phase II clinical study into MGB-BP-3, for the treatment of Clostridium difficile Infection (CDI). The study confirms that the drug has the potential to become the new gold standard, first-line treatment for CDI.
MGB Biopharma is backed by a range of investors, led by Edinburgh-based business angel investment syndicate, Archangels. Other investors include Barwell, TRICAPITAL, Syndicate Room and the Scottish Investment Bank. The company has also received support for its clinical programme from Innovate UK.
Read more HERE.
